NO975581D0 - Fremgangsmåte for å redusere bentap - Google Patents

Fremgangsmåte for å redusere bentap

Info

Publication number
NO975581D0
NO975581D0 NO975581A NO975581A NO975581D0 NO 975581 D0 NO975581 D0 NO 975581D0 NO 975581 A NO975581 A NO 975581A NO 975581 A NO975581 A NO 975581A NO 975581 D0 NO975581 D0 NO 975581D0
Authority
NO
Norway
Prior art keywords
steps
bone loss
reduce bone
reduce
loss
Prior art date
Application number
NO975581A
Other languages
English (en)
Norwegian (no)
Other versions
NO975581L (no
Inventor
George Joseph Cullinan
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975581D0 publication Critical patent/NO975581D0/no
Publication of NO975581L publication Critical patent/NO975581L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
NO975581A 1995-06-06 1997-12-03 Fremgangsmåte for å redusere bentap NO975581L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/467,475 US5599822A (en) 1995-06-06 1995-06-06 Methods for minimizing bone loss
PCT/US1996/008875 WO1996039138A1 (en) 1995-06-06 1996-06-05 Methods for minimizing bone loss

Publications (2)

Publication Number Publication Date
NO975581D0 true NO975581D0 (no) 1997-12-03
NO975581L NO975581L (no) 1997-12-03

Family

ID=23855853

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975581A NO975581L (no) 1995-06-06 1997-12-03 Fremgangsmåte for å redusere bentap

Country Status (22)

Country Link
US (1) US5599822A (ko)
EP (1) EP0747054B1 (ko)
JP (1) JPH11507051A (ko)
KR (1) KR19990022498A (ko)
CN (1) CN1192145A (ko)
AU (1) AU696209B2 (ko)
BR (1) BR9608389A (ko)
CA (1) CA2223055A1 (ko)
CO (1) CO4700446A1 (ko)
CZ (1) CZ382997A3 (ko)
DE (1) DE69623074T2 (ko)
EA (1) EA000763B1 (ko)
ES (1) ES2181849T3 (ko)
HU (1) HUP9900849A3 (ko)
IL (1) IL118590A (ko)
NO (1) NO975581L (ko)
PL (1) PL323935A1 (ko)
TR (1) TR199701507T1 (ko)
TW (1) TW372969B (ko)
WO (1) WO1996039138A1 (ko)
YU (1) YU34396A (ko)
ZA (1) ZA964778B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
WO2001035946A2 (en) * 1999-11-15 2001-05-25 New Millennium Pharmaceutical Research, Inc. Intranasal administration of raloxifene and tamoxifen
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1180364A1 (en) * 2000-08-15 2002-02-20 Octagene GmbH Steroid hormones as transfer agents
AU2003253129B2 (en) 2002-07-22 2008-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
BRPI0509788A (pt) * 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
WO2007044069A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
CN110809473A (zh) * 2017-06-01 2020-02-18 延世大学校产学协力团 用于预防或治疗骨相关疾病的药物组合物
CN108785264A (zh) * 2018-07-03 2018-11-13 威海贯标信息科技有限公司 一种达那唑片剂组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) * 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
DE69623074T2 (de) 2003-05-08
JPH11507051A (ja) 1999-06-22
AU696209B2 (en) 1998-09-03
ZA964778B (en) 1997-12-08
CZ382997A3 (cs) 1998-09-16
TW372969B (en) 1999-11-01
CO4700446A1 (es) 1998-12-29
DE69623074D1 (de) 2002-09-26
EA199800013A1 (ru) 1998-06-25
YU34396A (sh) 1999-07-28
HUP9900849A3 (en) 1999-11-29
ES2181849T3 (es) 2003-03-01
WO1996039138A1 (en) 1996-12-12
NO975581L (no) 1997-12-03
KR19990022498A (ko) 1999-03-25
EP0747054B1 (en) 2002-08-21
EA000763B1 (ru) 2000-04-24
CN1192145A (zh) 1998-09-02
EP0747054A2 (en) 1996-12-11
IL118590A (en) 1999-10-28
US5599822A (en) 1997-02-04
IL118590A0 (en) 1996-10-16
PL323935A1 (en) 1998-04-27
BR9608389A (pt) 1999-05-04
HUP9900849A2 (hu) 1999-09-28
AU6043096A (en) 1996-12-24
EP0747054A3 (en) 1997-03-05
CA2223055A1 (en) 1996-12-12
TR199701507T1 (xx) 1998-02-21

Similar Documents

Publication Publication Date Title
NO943852D0 (no) Fremgangsmåte for å hemme bentap
DK0747181T3 (da) Afgreningsordning
BR9610156A (pt) Composição em gel
DE69627026D1 (de) Osteosynthesevorrichtung
DE59608254D1 (de) Osteosynthesevorrichtung
ID16345A (id) Senyawa-senyawa heterosiklik
BR9607058A (pt) Composição
NO975581D0 (no) Fremgangsmåte for å redusere bentap
BR9606809A (pt) Composição inseticidamente ativa
DK0748583T3 (da) Mejetærsker
DE69617029T2 (de) Organoton-zusammensetzungen
PT9407T (pt) Colchao anatomico
DE69630414D1 (de) 5B4T-Kodierungsschema
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
NO982566D0 (no) Forbindelser
PT728814E (pt) Composicao betuminosa
DE69625730T2 (de) Endermatische Salbe
BR9609903A (pt) ComposiçÃo inseticidamente ativa
NO974170D0 (no) Polyazacykloalkan-forbindelser
DE69616374D1 (de) Germizide zusammensetzung
NO975560D0 (no) Fremgangsmåte for å redusere bentap
DE69603749T2 (de) Feste zusammensetzung
NO951060D0 (no) Prostaglandin F-estere
NO953081D0 (no) Fremgangsmåte for å fjerne tåke
FI944806A0 (fi) Kompaineri

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application